Immuneering Corp Cl A (IMRX)

$6.05 -0.48 (-7.35%)
Market Cap 251.50M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,545,400
Avg Vol 1,818,044
Day's Range N/A - N/A
Shares Out 41.57M
Stochastic %K 1%
Beta 0.47
Analysts Strong Sell
Price Target $14.42

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
stonk_looper
stonk_looper Oct. 5 at 7:41 AM
$IMRX Pharmaceutical development. High volatility on regulatory updates. No technical pattern established. Speculative only.
0 · Reply
vinmee
vinmee Oct. 4 at 5:08 PM
$IMRX marching towards 52 w low $1.10.. then reverse
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 4 at 3:28 PM
$IMRX Possible buyout Q1 or W2 2026
1 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:33 PM
$IMRX $DCROWN Maybe okay in the $5's but 1. I expect big move in the overall market near end of October and 2. which will usher in tax loss selling in November so many of these biotechs that have sold off over the past year taking a further hit. There may or may not be a January 2026 bounce effect so a well timed pick in November could net 80-200% in a few months on many of these. Good luck
0 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:13 PM
$IMRX Mapped out the predicted trajectory (perfectly!) and posted here (see below). I expect this to get into the $5's soon.
1 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:11 PM
$IMRX @OptimistJP Check out my prior posts...to me, this move was expected based on precedent / pattern revealed by other biotechs / partnerships / dilutions te past 2-3 year. At least IMRX did it after the share price increased substantially and rapidly vs other BioGrifters doing in on the way down.
0 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:07 PM
$IMRX @OptimistJP IMO, That is an embarrassing low number of shares purchased by insiders, a fraction of what many here likely own, and is a sell signal to me as it seems more like a stratagem rather than a strong conviction in the company's share price.
0 · Reply
johns45
johns45 Oct. 4 at 2:06 PM
$IMRX HBM a Switzerland based Biotechnology investment corp just took a 5.7% stake in IMRX...they are really smart!!!!
1 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:01 PM
$IMRX @Ehud8 imo, Options available = likely going down to the $5's. Now shorts can hedge.
0 · Reply
Power2k
Power2k Oct. 4 at 2:27 AM
$IMRX https://ir.immuneering.com/sec-filings/sec-filing/schedule-13g/0001104659-25-096664
2 · Reply
Latest News on IMRX
Immuneering Corporation - Special Call

Sep 29, 2025, 4:37 PM EDT - 5 days ago

Immuneering Corporation - Special Call

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 26, 2025, 4:01 PM EDT - 8 days ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 2:19 PM EDT - 9 days ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 25, 2025, 12:08 AM EDT - 10 days ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 10 days ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 24, 2025, 4:01 PM EDT - 10 days ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 19 days ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 10, 2025, 7:00 AM EDT - 25 days ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 5 weeks ago

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Aug 25, 2025, 8:00 AM EDT - 5 weeks ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 6 weeks ago

Immuneering Announces $25 Million Private Placement

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 7 weeks ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 3 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 3 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 4 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 5 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 6 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 7 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 7 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 8 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 9 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 10 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Dec 13, 2024, 2:10 PM EST - 10 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 10 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 11 months ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 11 months ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 20, 2024, 8:00 AM EST - 1 year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Immuneering Announces Participation in February Investor Conferences

Feb 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Announces Participation in February Investor Conferences

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Dec 12, 2023, 8:00 AM EST - 1 year ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 4:05 PM EST - 2 years ago

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

stonk_looper
stonk_looper Oct. 5 at 7:41 AM
$IMRX Pharmaceutical development. High volatility on regulatory updates. No technical pattern established. Speculative only.
0 · Reply
vinmee
vinmee Oct. 4 at 5:08 PM
$IMRX marching towards 52 w low $1.10.. then reverse
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 4 at 3:28 PM
$IMRX Possible buyout Q1 or W2 2026
1 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:33 PM
$IMRX $DCROWN Maybe okay in the $5's but 1. I expect big move in the overall market near end of October and 2. which will usher in tax loss selling in November so many of these biotechs that have sold off over the past year taking a further hit. There may or may not be a January 2026 bounce effect so a well timed pick in November could net 80-200% in a few months on many of these. Good luck
0 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:13 PM
$IMRX Mapped out the predicted trajectory (perfectly!) and posted here (see below). I expect this to get into the $5's soon.
1 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:11 PM
$IMRX @OptimistJP Check out my prior posts...to me, this move was expected based on precedent / pattern revealed by other biotechs / partnerships / dilutions te past 2-3 year. At least IMRX did it after the share price increased substantially and rapidly vs other BioGrifters doing in on the way down.
0 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:07 PM
$IMRX @OptimistJP IMO, That is an embarrassing low number of shares purchased by insiders, a fraction of what many here likely own, and is a sell signal to me as it seems more like a stratagem rather than a strong conviction in the company's share price.
0 · Reply
johns45
johns45 Oct. 4 at 2:06 PM
$IMRX HBM a Switzerland based Biotechnology investment corp just took a 5.7% stake in IMRX...they are really smart!!!!
1 · Reply
LabPsycho
LabPsycho Oct. 4 at 2:01 PM
$IMRX @Ehud8 imo, Options available = likely going down to the $5's. Now shorts can hedge.
0 · Reply
Power2k
Power2k Oct. 4 at 2:27 AM
$IMRX https://ir.immuneering.com/sec-filings/sec-filing/schedule-13g/0001104659-25-096664
2 · Reply
BinaryLogic
BinaryLogic Oct. 3 at 11:24 PM
$IMRX As mentioned-the stock was forced down to the $6.0 resistance line to claim as support. Look for a material move upward (possible) near term from this level once this support/resistance line is confirmed. 50%+ upside just to reach the Sanofi placement at $9.32.
3 · Reply
Ehud8
Ehud8 Oct. 3 at 11:12 PM
$IMRX crazy price action AH
1 · Reply
dcrown
dcrown Oct. 3 at 9:54 PM
$IMRX Sanofi doesn’t know what it’s doing neither the investors who put $175 mills into this new paradigm lol Sanofi's latest move, and the $175 million it attracted, proves you don't need a map to find the gold
0 · Reply
essiepaul
essiepaul Oct. 3 at 8:36 PM
$IMRX bunch of stiffs in this one. These shorts would sell their mother for a nickel
0 · Reply
Ehud8
Ehud8 Oct. 3 at 8:28 PM
$IMRX 50k short shares dumped at close
0 · Reply
Ehud8
Ehud8 Oct. 3 at 7:58 PM
$IMRX bought @ 6.10
0 · Reply
BinaryLogic
BinaryLogic Oct. 3 at 7:53 PM
$IMRX [As stated] Institutions are walking the SP straight down to the $6.0 support line. 50-100% upside (IMO) from that level near/intermediate term.
3 · Reply
nUme22
nUme22 Oct. 3 at 7:51 PM
$IMRX buying yyyuuugeeeee.. we soar next week on..
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 7:49 PM
$IMRX $IMRX Peter is down -$23,500
0 · Reply
Fonzinatrix
Fonzinatrix Oct. 3 at 7:29 PM
$IMRX bought more🤣🙈
1 · Reply
TheHyena
TheHyena Oct. 3 at 6:34 PM
$IMRX insane
0 · Reply
velle
velle Oct. 3 at 6:21 PM
$IMRX MCAP lower than 400M now Meanwhile they are sitting on 200M+$ And telling results from the pancreas cancer trial ph2
0 · Reply